BMA three-lens brief
Evidence-based stock research on BMA. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
Underperforming SPY by 17.1pp over 30 days. · Trading >3% below the 50-day MA — short-term weakness.
- Trading >3% below the 50-day MA — short-term weakness.
- Underperforming SPY by 17.1pp over 30 days.
- Analyst mean target $112.35 — 43% above current (9 analysts).
BMA closed at $78.83 (-0.43%) as of 2026-09-11. Market cap: $5.04B. P/E (trailing) 20.0. Price is below the 50-day MA and below the 200-day MA. Positives: analyst mean target $112.35 — 43% above current (9 analysts).. Concerns: trading >3% below the 50-day MA — short-term weakness.; underperforming SPY by 17.1pp over 30 days.. Last quarter: Revenue $1.25T, net income $206.63B.
Why three lenses on BMA, not one.
A single reasoning model has blind spots it doesn’t know about. We examine BMAacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/BMA" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath BMA brief"></iframe>